...Good morning, everyone. My name is Yigal Nochomovitz. I'm one of the biotech analysts here at Citi, joined by my colleague, Neena Garg. So we're here to talk about rare diseases. We have 3 outstanding companies to engage with from Ultragenyx, Eric Crombez, Chief Medical Officer of Ultragenyx Gene Therapy; from Decibel Therapeutics, Laurence Reid, CEO; and from Rocket Pharma, Gaurav Shah, also CEO. We'll try to keep it more of a high-level discussion, but I do want to give each of you just a very quick 2 or 3 minutes just to give everyone a quick overview of the company, what are the key assets, potentially key data points over the next to 2 months and then we can go into more of a discussion about rare disease drug development. Eric Crombez Great. Thanks for the opportunity. Again, I'm Eric Crombez, so I'm the Chief Medical Officer for Ultragenyx Gene Therapy and Inborn Errors of Metabolism programs. Been with Ultragenyx for about 5 years now and really founded and dedicated to the treatment...
